{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:12:23Z","timestamp":1759961543770,"version":"3.40.5"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,11,30]],"date-time":"2014-11-30T00:00:00Z","timestamp":1417305600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s10067-014-2830-9","type":"journal-article","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T14:17:56Z","timestamp":1417443476000},"page":"201-205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Methotrexate revisited: considerations for subcutaneous administration in RA"],"prefix":"10.1007","volume":"34","author":[{"given":"Randy","family":"Jay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,30]]},"reference":[{"issue":"13 suppl","key":"2830_CR1","first-page":"S295","volume":"18","author":"A Gibofsky","year":"2012","unstructured":"Gibofsky A (2012) Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care 18(13 suppl):S295\u2013S302","journal-title":"Am J Manag Care"},{"key":"2830_CR2","unstructured":"Centers for Disease Control and Prevention. Rheumatoid arthritis. www.cdc.gov\/arthritis\/basics\/rheumatoid.htm . Accessed August 19, 2014"},{"issue":"4","key":"2830_CR3","first-page":"286","volume":"5","author":"M Cojocaru","year":"2010","unstructured":"Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD, Tanasecu R (2010) Extra-articular manifestations in rheumatoid arthritis. Maedica (Buchar) 5(4):286\u2013291","journal-title":"Maedica (Buchar)"},{"issue":"3","key":"2830_CR4","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2009.120899","volume":"70","author":"H K\u00e4llberg","year":"2011","unstructured":"K\u00e4llberg H, Ding B, Padyukov L et al (2011) Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis 70(3):508\u2013511","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2830_CR5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/ar2585","volume":"11","author":"JE Oliver","year":"2009","unstructured":"Oliver JE, Silman AJ (2009) What epidemiology has told us about risk factors and aetiopathogenesis in rheumatic diseases. Arthritis Res Ther 11(3):223","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"2830_CR6","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/art.22597","volume":"56","author":"M Pedersen","year":"2007","unstructured":"Pedersen M, Jacobsen S, Garred P et al (2007) Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case\u2013control study in Denmark. Arthritis Rheum 56(5):1446\u20131453","journal-title":"Arthritis Rheum"},{"issue":"10 suppl 1","key":"2830_CR7","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.amjmed.2008.06.011","volume":"121","author":"SE Gabriel","year":"2008","unstructured":"Gabriel SE (2008) Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med 121(10 suppl 1):S9\u2013S14","journal-title":"Am J Med"},{"issue":"5","key":"2830_CR8","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1016\/j.ijcard.2013.07.233","volume":"168","author":"WS Chung","year":"2013","unstructured":"Chung WS, Lin CL, Peng CL et al (2013) Rheumatoid arthritis and risk of acute myocardial infarction\u2014a nationwide retrospective cohort study. Int J Cardiol 168(5):4750\u20134754","journal-title":"Int J Cardiol"},{"issue":"suppl 1","key":"2830_CR9","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/1478-6354-13-S1-S4","volume":"13","author":"G Schett","year":"2011","unstructured":"Schett G, Coates LC, Ash ZR, Finzel S, Conaghan PG (2011) Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther 13(suppl 1):S4","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"2830_CR10","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1136\/ard.2007.076521","volume":"66","author":"C Turesson","year":"2007","unstructured":"Turesson C, Eberhardt K, Jacobson LT, Lindqvist E (2007) Incidence and predictors of severe extra-articular disease manifestations in an early rheumatoid arthritis inception cohort. Ann Rheum Dis 66(11):1543\u20131544","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2830_CR11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","volume":"64","author":"JA Singh","year":"2012","unstructured":"Singh JA, Furst DE, Bharat A et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 64(5):625\u2013639","journal-title":"Arthritis Care Res"},{"issue":"3","key":"2830_CR12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73(3):492\u2013509","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2830_CR13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/1759720X11408635","volume":"3","author":"J Braun","year":"2011","unstructured":"Braun J (2011) Methotrexate: optimizing the efficacy in rheumatoid arthritis. Ther Adv Musculoskel Dis 3(3):151\u2013158","journal-title":"Ther Adv Musculoskel Dis"},{"issue":"5 suppl 3","key":"2830_CR14","first-page":"S179","volume":"21","author":"T Pincus","year":"2003","unstructured":"Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS (2003) Methotrexate as the \u201canchor drug\u201d for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 21(5 suppl 3):S179\u2013S185","journal-title":"Clin Exp Rheumatol"},{"issue":"5 suppl 61","key":"2830_CR15","first-page":"S46","volume":"28","author":"J Braun","year":"2010","unstructured":"Braun J (2010) Optimal administration and dosage of methotrexate. Clin Exp Rheumatol 28(5 suppl 61):S46\u2013S51","journal-title":"Clin Exp Rheumatol"},{"key":"2830_CR16","first-page":"16","volume":"124","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt ME (2013) Methotrexate in rheumatoid arthritis: a quarter century of development. Trans Am Clin Climatol Assoc 124:16\u201325","journal-title":"Trans Am Clin Climatol Assoc"},{"issue":"3","key":"2830_CR17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/BOR.0b013e328329c79d","volume":"21","author":"J Braun","year":"2009","unstructured":"Braun J, Rau R (2009) An update on methotrexate. Curr Opin Rheumatol 21(3):216\u2013223","journal-title":"Curr Opin Rheumatol"},{"key":"2830_CR18","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJM198503283121303","volume":"312","author":"ME Weinblatt","year":"1985","unstructured":"Weinblatt ME et al (1985) Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312:818\u2013822","journal-title":"N Engl J Med"},{"key":"2830_CR19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJM199507203330301","volume":"333","author":"P Tugwell","year":"1995","unstructured":"Tugwell P, Pincus T, Yocum D et al (1995) Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 333:137\u2013141","journal-title":"N Engl J Med"},{"key":"2830_CR20","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199605163342002","volume":"334","author":"JR O\u2019Dell","year":"1996","unstructured":"O\u2019Dell JR, Haire CE, Erikson N et al (1996) Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 334:1287\u20131291","journal-title":"N Engl J Med"},{"key":"2830_CR21","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","volume":"363","author":"L Klareskog","year":"2004","unstructured":"Klareskog L, Van der Heijde D, De Jager JP, TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 363:675\u2013681","journal-title":"Lancet"},{"key":"2830_CR22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF et al (2006) The PREMIER study\u2014a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26\u201337","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2830_CR23","first-page":"168","volume":"65","author":"H Tian","year":"2007","unstructured":"Tian H, Cronstein BN (2007) Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis 65(3):168\u2013173","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"2830_CR24","unstructured":"Donahue KE, Jonas DE, Hansen RA, et al (2012) Drug therapy for rheumatoid arthritis in adults: an update. Comparative effectiveness review no. 55. (Prepared by RTI-UNC Evidence-based Practice Center under Contract No. 290-02-0016-I.) Rockville, MD: Agency for Healthcare Research and Quality. April. www.effectivehealthcare.ahrq.gov\/reports\/final.cfm"},{"key":"2830_CR25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pr.57.2.3","volume":"57","author":"BN Cronstein","year":"2005","unstructured":"Cronstein BN (2005) Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 57:163\u2013172","journal-title":"Pharmacol Rev"},{"key":"2830_CR26","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/ard.60.8.729","volume":"60","author":"M Cutolo","year":"2001","unstructured":"Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH (2001) Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 60:729\u2013735","journal-title":"Ann Rheum Dis"},{"key":"2830_CR27","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1002\/art.24034","volume":"58","author":"JM Dalrymple","year":"2008","unstructured":"Dalrymple JM, Stamp LK, O\u2019Donnell JL, Chapman PT, Zhang M, Barclay ML (2008) Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 58:3299\u20133308","journal-title":"Arthritis Rheum"},{"issue":"12","key":"2830_CR28","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.3899\/jrheum.110481","volume":"38","author":"LK Stamp","year":"2011","unstructured":"Stamp LK, Barclay ML, O\u2019Donnell JL et al (2011) Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. J Rheumatol 38(12):2540\u20132547","journal-title":"J Rheumatol"},{"issue":"10","key":"2830_CR29","first-page":"S147","volume":"60","author":"JM Kremer","year":"2009","unstructured":"Kremer JM, Zablocki R, Dervieux T (2009) Switching from oral to parenteral methotrexate administration produces clinical improvements through selective accumulation of long-chains methotrexate polyglutamates. Arthritis Rheum 60(10):S147, Abstract 400","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2830_CR30","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/art.20460","volume":"50","author":"T Dervieux","year":"2004","unstructured":"Dervieux T, Furst D, Dein DO et al (2004) Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 50(9):2766\u20132774","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2830_CR31","first-page":"563","volume":"32","author":"U Pichlmeier","year":"2014","unstructured":"Pichlmeier U, Heuer KU (2014) Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. Clin Exp Rheumatol 32(4):563\u2013571","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"2830_CR32","first-page":"645","volume":"31","author":"M Hoekstra","year":"2004","unstructured":"Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M (2004) Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 31(4):645\u2013648","journal-title":"J Rheumatol"},{"issue":"5 suppl 61","key":"2830_CR33","first-page":"S27","volume":"28","author":"EN Roon Van","year":"2010","unstructured":"Van Roon EN, van de Laar MA (2010) Methotrexate bioavailability. Clin Exp Rheumatol 28(5 suppl 61):S27\u2013S32","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"2830_CR34","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/annrheumdis-2014-205228","volume":"73","author":"MH Schiff","year":"2014","unstructured":"Schiff MH, Jaffe JS, Freundlich B (2014) Head-to-head, randomized, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses \u226515\u00a0mg may be overcome with subcutaneous administration. Ann Rheum Dis 73(8):1549\u20131551","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2830_CR35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.23144","volume":"58","author":"J Braun","year":"2008","unstructured":"Braun J, K\u00e4stner P, Flacenberg P et al (2008) Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis. Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 58(1):73\u201381","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2830_CR36","first-page":"686","volume":"50","author":"S Agarwal","year":"2009","unstructured":"Agarwal S, Zaman T, Handa R (2009) Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Singapore Med J 50(7):686\u2013692","journal-title":"Singapore Med J"},{"issue":"7","key":"2830_CR37","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2008.094474","volume":"68","author":"K Visser","year":"2009","unstructured":"Visser K, Katchamart W, Loza E et al (2009) Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 68(7):1086\u20131093","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2830_CR38","first-page":"207","volume":"47","author":"L Rutkowska-Sak","year":"2009","unstructured":"Rutkowska-Sak L, Rell-Bakalarska M, Lisowska B (2009) The role of oral or subcutaneous routes of administration of small doses of methotrexate in the reduction of side effects from the gastrointestinal tract. Rheumatolgia 47(4):207\u2013211","journal-title":"Rheumatolgia"},{"key":"2830_CR39","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3109\/s10165-012-0685-y","volume":"23","author":"E Dalkilic","year":"2013","unstructured":"Dalkilic E, Sahbazlar M, Gullulu M et al (2013) The time course of gastric methotrexate intolerance in patients with rheumatoid arthritis and psoriatic arthritis. Mod Rheumatol 23:525\u2013528","journal-title":"Mod Rheumatol"},{"issue":"suppl","key":"2830_CR40","first-page":"iii135","volume":"51","author":"DGI Scott","year":"2012","unstructured":"Scott DGI, Claydon P, Ellis C et al (2012) A retrospective study of the effects of switching from oral to subcutaneous methotrexate: the methotrexate evaluation of Norwich treatment outcomes in rheumatoid arthritis (MENTOR) study. Rheumatol 51(suppl):iii135, Abstract 221","journal-title":"Rheumatol"},{"issue":"3","key":"2830_CR41","first-page":"592","volume":"68","author":"SM Keidel","year":"2009","unstructured":"Keidel SM, Chan A (2009) Parenteral methotrexate use in patients with chronic rheumatoid arthritis is effective and produces a lasting response. Ann Rheum Dis 68(3):592, Abstract SAT0151","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2830_CR42","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1136\/ard.2009.124065","volume":"69","author":"MF Bakker","year":"2010","unstructured":"Bakker MF, Jacobs JWG, Welsing PMJ et al (2010) Are switches from oral methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Ann Rheum Dis 69(10):1849\u20131852","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2830_CR43","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1136\/annrheumdis-2012-eular.593","volume":"71","author":"A Liakos","year":"2012","unstructured":"Liakos A, Batley M, Hammond T et al (2012) Subcutaneous methotrexate is more efficacious and better tolerated than oral methotrexate: the experience of a large group of patients in the rheumatology department of a district general hospital. Ann Rheum Dis 71(3):672, Abstract AB0593","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2830_CR44","first-page":"37","volume":"5","author":"P Chaudhari","year":"2008","unstructured":"Chaudhari P (2008) The impact of rheumatoid arthritis and biologics on employers and payers. Biotechnol Healthc 5(2):37\u201344","journal-title":"Biotechnol Healthc"},{"issue":"2","key":"2830_CR45","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/rheumatology\/kem306","volume":"47","author":"A Bharadwaj","year":"2008","unstructured":"Bharadwaj A, Agrawal S, Batley M, Hammond A (2008) Use of parenteral methotrexate significantly reduces the need for biological therapy. Rheumatol 47(2):222","journal-title":"Rheumatol"},{"key":"2830_CR46","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.3899\/jrheum.120091","volume":"39","author":"R Hassanzadeh","year":"2012","unstructured":"Hassanzadeh R et al (2012) Subcutaneous MTX to cut costs? J Rheumatol 39:1764\u20131765","journal-title":"J Rheumatol"},{"issue":"11","key":"2830_CR47","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s10067-013-2318-z","volume":"32","author":"R Fitzpatrick","year":"2013","unstructured":"Fitzpatrick R, Scott DGI, Keary I (2013) Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate. Clin Rheumatol 32(11):1605\u20131612","journal-title":"Clin Rheumatol"},{"key":"2830_CR48","first-page":"51","volume":"61","author":"R Fitzpatrick","year":"2012","unstructured":"Fitzpatrick R (2012) Pharmacoeconomics of subcutaneous methotrexate. Hosp Pharm Eur 61:51\u201354","journal-title":"Hosp Pharm Eur"},{"issue":"3","key":"2830_CR49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5001\/omj.2011.38","volume":"26","author":"B Jimmy","year":"2011","unstructured":"Jimmy B, Jose J (2011) Patient medication adherence: measures in daily practice. Oman Med J 26(3):155\u2013159","journal-title":"Oman Med J"},{"issue":"3","key":"2830_CR50","first-page":"350","volume":"31","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Combe B, Burmester G (2013) Understanding the patient perspective - results of the Rheumatoid Arthritis: Insights, Strategies & Expectations (RAISE) patient needs survey. Clin Exp Rheumatol 31(3):350\u2013357","journal-title":"Clin Exp Rheumatol"},{"key":"2830_CR51","unstructured":"Pachon JA, Kivitz AJ, Heuer K-U, Pichlmeier U (2013) Successful self-administration of methotrexate in rheumatoid arthritis patients using a prefilled autoinjector pen. Poster presented at the ACR\/ARHP Annual Meeting. San Diego, California; October 26\u201330. Abstract 1354."}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2830-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-014-2830-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2830-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T22:02:02Z","timestamp":1747173722000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-014-2830-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,30]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["2830"],"URL":"https:\/\/doi.org\/10.1007\/s10067-014-2830-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2014,11,30]]}}}